Prof Mary Collins

Photo

Personal Profile

Name: Mary Collins Email: mary.collins@ucl.ac.uk
Title: Prof Tel: 020 7679 0883
Department: Div of Infection & Immunity Fax: 020 7679 0876
Position: Professor of Immunology Address: Maple House, 149 Tottenham Court Road, London, W1T 7JA
Research Domain: Cancer, Global Health, Infection, Immunology & Inflammation, Personalised Medicine Web Page: Personal Web Page

Profile

Research Description

The research team of approximately 10 PhD students and post-doctoral fellows engineer viruses for experimental and clinical gene delivery. Recently they have produced the first stable packaging for lentiviral vectors, and have investigated the use of lentiviral vectors as cancer vaccines.

Research Activities

Engineering viruses for gene delivery

Hepatology

Immunopathogenesis of hepatitis B virus infection

Retrovirus in gene therapy and xenotransplantation

Education Description

UCL Collaborators

Prof William Rosenberg; Prof Mala Maini; Dr Michael Jacobs; Prof Geoffrey Dusheiko; Dr Richard Gilson; Prof Arne Akbar; Prof Dame Anne Johnson; Dr Yasu Takeuchi; Prof Greg Towers

External Collaborators

Publications

    2013

    • Collins MKL (2013). Scholarship, extinction and the Irish Elk. In Carnall M (Ed.), Conversation Pieces: Inspirational objects in UCL's historic collections (pp. 46 - 47). : Shire Publications Ltd.

    2012

    • Zhang F, Knight S, Collins M, Takeuchi Y, Antoniou M, Thrasher AJ (2012). Improved safety of Lentiviral vectors containing silencing resistant A2UCOE regulatory elements.
    • Montiel-Equihua CA, Zhang L, Knight S, Saadeh H, Scholz S, Carmo M, Alonso-Ferrero ME, Blundell MP, Monkeviciute A, Schulz R, Collins M, Takeuchi Y, Schmidt M, Fairbanks L, Antoniou M, Thrasher AJ, Gaspar HB (2012). Development of a gene expression system for enhanced erythroid expression.
    • Alpizar YA, Rivera AY, Fernández LE, Ramírez BS, Karwacz K, Arce F, Collins MK (2012). Lentiviral vector followed by protein immunisation breaks tolerance against the self-antigen Her1 and results in lung cancer immunotherapy. Journal of Gene Medicine, 14(3), 151 - 157. doi:10.1002/jgm.2606
    • Montiel-Equihua CA, Zhang L, Knight S, Saadeh H, Scholz S, Carmo M, Alonso-Ferrero ME, Blundell MP, Monkeviciute A, Schulz R, Collins M, Takeuchi Y, Schmidt M, Fairbanks L, Antoniou M, Thrasher AJ, Gaspar HB (2012). The β-globin locus control region in combination with the EF1α short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity.. Mol Ther, 20(7), 1400 - 1409. doi:10.1038/mt.2012.50
    • Knight S, Zhang F, Mueller-Kuller U, Bokhoven M, Gupta A, Broughton T, Sha S, Antoniou MN, Brendel C, Grez M, Thrasher AJ, Collins M, Takeuchi Y (2012). Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing.. J Virol, 86(17), 9088 - 9095. doi:10.1128/JVI.00485-12

    2011

    • Cire S, Collins MK, Buchholz C, Galy A (2011). In vivo immunization against male antigens and GFP, with lentiviruses targeted to MHC class II positive cells. HUMAN GENE THERAPY, 22(10), A69 - A69.
    • Montiel-Equihua CA, Zhang L, Knight S, Collins M, Saadeh H, Schulz R, Scholz S, Schmidt M, Carmo M, Alonso-Ferrero ME, Blundell MP, Fairbanks LD, Monkeviciute A, Antoniou M, Thrasher AJ, Gaspar HB (2011). Development of a gene expression system for enhanced erythroid expression. HUMAN GENE THERAPY, 22(10), A105 - A105.
    • Alpizar YA, Chain B, Collins MK, Greenwood J, Katz D, Stauss HJ, Mitchison NA (2011). Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.. Cancer Immunol Immunother, 60(8), 1127 - 1135. doi:10.1007/s00262-011-0985-7
    • Lopes L, Dewannieux M, Takeuchi Y, Collins MK (2011). A lentiviral vector pseudotype suitable for vaccine development.. J Gene Med, 13(3), 181 - 187. doi:10.1002/jgm.1553
    • Ageichik A, Buchholz CJ, Collins MK (2011). Lentiviral vectors targeted to MHC II are effective in immunization.. Hum Gene Ther, 22(10), 1249 - 1254. doi:10.1089/hum.2010.184
    • Schneider IC, Eckhardt M, Brynza J, Collins MK, Cichutek K, Buchholz CJ (2011). Escape from R-peptide deletion in a gamma-retrovirus. VIROLOGY, 418(2), 85 - 92. doi:10.1016/j.virol.2011.07.011
    • Cire S, Collins MK, Buchholz CJ, Galy A (2011). An experimental model set-up to study MHC class II targeted gene transfer in antigen-presenting-cells.
    • Winkler S, Takeuchi Y, Young N, Thorpe R, Collins M, Zhao Y (2011). SEC purification of lentiviral vectors: comparison of RD114 pseudotypes produced by stable packaging cells and transiently produced VSV-G pseudotypes. HUM GENE THER, 22(10), A109 - A110.
    • Arce F, Breckpot K, Stephenson H, Karwacz K, Ehrenstein MR, Collins M, Escors D (2011). Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis.. Arthritis Rheum, 63(1), 84 - 95. doi:10.1002/art.30099
    • Shimizu A, Baratchian M, Takeuchi Y, Escors D, Macdonald D, Barrett T, Bagneris C, Collins M, Noursadeghi M (2011). Kaposi's sarcoma-associated herpesvirus vFLIP and human T cell lymphotropic virus type 1 Tax oncogenic proteins activate IkappaB kinase subunit gamma by different mechanisms independent of the physiological cytokine-induced pathways.. J Virol, 85(14), 7444 - 7448. doi:10.1128/JVI.02337-10
    • Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M, Escors D (2011). PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells.. EMBO Mol Med, 3(10), 581 - 592. doi:10.1002/emmm.201100165
    • Mueller-Kuller U, Brendel C, Knight SB, Antoniou M, Collins M, Grez M (2011). Development of safety improved lentiviral vectors containing ubiquitous chromatin opening elements. HUMAN GENE THERAPY, 22(10), A105 - A105.

    2010

    • Perro M, Tsang J, Xue SA, Escors D, Cesco-Gaspere M, Pospori D, Gao L, Hart D, Collins M, Stauss H, Morris EC (2010). Lentiviral Vectors for TCR Gene Transfer: Improved Function of TCR-Transduced T Cells After Non-Activating Cytokine-Mediated Transduction.
    • Arce F, Breckpot K, Stephenson H, Karwacz K, Ehrenstein MR, Collins M, Escors D (2010). Therapeutic application of selective ERK activation for the treatment of inflammatory arthritis.
    • Knight S, Bokhoven M, Collins M, Takeuchi Y (2010). Effect of the Internal Promoter on Insertional Gene Activation by Lentiviral Vectors with an Intact HIV Long Terminal Repeat (vol 84, pg 4856, 2010). J VIROL, 84(12), 6263 - 6263. doi:10.1128/JVI.00774-10
    • Knight SB, Bokhoven M, Gubta A, Zhang F, Antoniou M, Thrasher A, Collins M, Takeuchi Y (2010). Insertional Mutagenesis by Lentiviral Vectors.
    • Perro M, Tsang J, Xue SA, Escors D, Cesco-Gaspere M, Pospori C, Gao L, Hart D, Collins M, Stauss H, Morris EC (2010). Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer.. Gene Ther, 17(6), 721 - 732. doi:10.1038/gt.2010.4
    • Arce F, Breckpot K, Ehrenstein M, Collins MK, Escors D (2010). Targeted Activation of ERK Pathway with Lentiviral Vectors to Induce Antigen-Specific Peripheral Tolerance.
    • Knight S, Bokhoven M, Collins M, Takeuchi Y (2010). Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat.. J Virol, 84(9), 4856 - 4859. doi:10.1128/JVI.02476-09
    • Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, Van Lint S, Keyaerts M, Collins M (2010). HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.. J Virol, 84(11), 5627 - 5636. doi:10.1128/JVI.00014-10
    • Macdonald D, Brindle NR, Whelan M, Maini MK, Collins MK, Rosenberg WM (2010). LENTIVIRAL VECTORS CO-EXPRESSING HEPATITIS-B CORE AND VFLIP INDUCE POTENT CD8 T-CELL AND ANTIBODY RESPONSES IN HLA-A2 TRANSGENIC MICE.
    • Macdonald DC, Whelan M, Escors D, Rosenberg WMC, Collins MK (2010). Lentiviral Vectors Encoding Influenza A Nucleprotein and vFLIP Induce Potent CD8 T-Cell Responses and Confer Protection Against Lethal Flu Challenge.
    • Cohen-Haguenauer O, Creff N, Cruz P, Tunc C, Aïuti A, Baum C, Bosch F, Blomberg P, Cichutek K, Collins M, Danos O, Dehaut F, Federspiel M, Galun E, Garritsen H, Hauser H, Hildebrandt M, Klatzmann D, Merten OW, Montini E, O'Brien T, Panet A, Rasooly L, Scherman D, Schmidt M, Schweitzer M, Tiberghien P, Vandendriessche T, Ziehr H, Ylä-Herttuala S, von Kalle C, Gahrton G, Carrondo M (2010). Relevance of an academic GMP Pan-European vector infra-structure (PEVI).. Curr Gene Ther, 10(6), 414 - 422.

    2009

    • Collins M (2009). Lentiviral Vectors as Vaccines. HUMAN GENE THERAPY, 20(9), 1030 - 1030.
    • Collins M (2009). Lentiviral Vectors as Vaccines. HUMAN GENE THERAPY, 20(6), 658 - 659.
    • Ageichik A, Buchholz C, Collins M (2009). Efficient immunization by a novel lentivector re-targeted to MHC II.
    • Karwacz K, Apolonia L, Escors D, Thrasher A, Collins M (2009). Non-Integrating Lentiviral Vectors for Vaccination.
    • Bokhoven M, Stephen SL, Knight S, Gevers EF, Robinson IC, Takeuchi Y, Collins MK (2009). Insertional gene activation by lentiviral and gammaretroviral vectors.. J Virol, 83(1), 283 - 294. doi:10.1128/JVI.01865-08
    • Karwacz K, Mukherjee S, Apolonia L, Blundell MP, Bouma G, Escors D, Collins MK, Thrasher AJ (2009). Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy.. J Virol, 83(7), 3094 - 3103. doi:10.1128/JVI.02519-08
    • Mueller-Kuller U, Brendel C, Knight S, Antoniou M, Collins M, Grez M (2009). Development of safety improved lentiviral vectors containing ubiquitous chromatin opening elements.
    • Gennari F, Lopes L, Verhoeyen E, Marasco W, Collins MK (2009). Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells.. Hum Gene Ther, 20(6), 554 - 562. doi:10.1089/hum.2008.189
    • Rowe HM, Lopes L, Brown N, Efklidou S, Smallie T, Karrar S, Kaye PM, Collins MK (2009). Expression of vFLIP in a lentiviral vaccine vector activates NF-{kappa}B, matures dendritic cells, and increases CD8+ T-cell responses.. J Virol, 83(4), 1555 - 1562. doi:10.1128/JVI.00709-08
    • Arce F, Rowe HM, Chain B, Lopes L, Collins MK (2009). Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization.. Mol Ther, 17(9), 1643 - 1650. doi:10.1038/mt.2009.149

    2008

    • Knight S, Bokhoven M, Gupta A, Ceylan M, Zhang F, Antoniou M, Thrasher A, Takeuchi Y, Collins M (2008). Insertional mutagenesis by retroviral and lentiviral vectors.
    • Arce F, Rowe H, Lopes L, Escors D, Chain B, Collins MK (2008). Sustained antigen presentation after lentiviral immunization.
    • Efklidou S, Bailey R, Field N, Noursadeghi M, Collins MK (2008). vFLIP from KSHV inhibits anoikis of primary endothelial cells. Journal of Cell Science, 121, 450 - 457.
    • Ageichik A, Collins MK, Dewannieux M (2008). Lentivector targeting to dendritic cells. Molecular Therapy, 16(6), 1008 - 1009.
    • Bagnéris C, Ageichik AV, Cronin N, Wallace B, Collins MK, Boshoff C, Waksman G, Barrett T (2008). Crystal structure of a vFlip-IKKgamma complex: insights into viral activation of the IKK signalosome.. Molecular Cell, 30(5), 620 - 631. doi:10.1016/j.molcel.2008.04.029
    • Dewannieux M, Collins MK (2008). Spontaneous heteromerization of gammaretroviral envelope proteins: a possible novel mechanism of retrovirus restriction. Journal of Virology, , - .
    • Escors D, Lopes L, Lin R, Hiscott J, Akira S, Davis RJ, Collins MK (2008). Targeting dendritic cell signalling to regulate the response to immunization. Blood, 111, 3050 - 3061.
    • Lopes L, Gileadi U, Dewannieux M, Bailey R, Ikeda Y, Whittacker C, Collin M, Cerundolo V, Ariizumi K, Collins MK (2008). Immunisation with a lentivector that targets tumour antigen expression to dendritic cells induces potent CD8+ and CD4+ T cell responses. Journal of Virology, 82(1), 86 - 95.

    2007

    • Bokhoven M, Stephen S, Takeuchi Y, Collins MK (2007). Insertional mutagenesis by retroviral and lentiviral vectors.
    • Apolonia L, Waddington S, Fernandes C, Ward N, Bouma G, Thrasher A, Collins MK, Philpott N (2007). Long-term expression from non-integrating lentiviral vectors in muscle.
    • Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP, Thrasher AJ, Collins MK, Philpott NJ (2007). Stable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors. Mol Ther., , - .
    • Pichlmair A, Diebold SS, Gschmeissner S, Takeuchi Y, Ikeda Y, Collins MK, Reis e Sousa C (2007). Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. Journal of Virology, 81(2), 539 - 547.
    • Escors D, Lopes L, Collins MK (2007). Modulation of the immune response by lentivector targeting of intracellular pathways.
    • Pichlmair A, Diebold SS, Gschmeissner S, Takeuchi Y, Ikeda Y, Collins MK, Reis E Sousa C (2007). Tubulovesicular structures within VSV-G pseudotyped lentiviral vector preparations carry DNA and stimulate anti-viral responses via toll-like receptor 9. Journal of Virology, 81(2), 539 - 547.
    • Selden C, Mellor N, Rees M, Laurson J, Kirwan M, Escors D, Collins M, Hodgson H (2007). Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. J Gene Med., 9(2), 67 - 76. doi:10.1002/jgm.1000
    • Karwacz K, Apolonia L, Escors D, Lopes L, Collins MK (2007). Non-integrating lentiviral vectors for immunization.

    2006

    • Rowe HM, Lopes L, Ikeda Y, Bailey R, Barde I, Zenke M, Chain BM, Collins MK (2006). Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.. Mol Ther, 13(2), 310 - 319. doi:10.1016/j.ymthe.2005.08.025
    • Lopes L, Fletcher K, Ikeda Y, Collins M (2006). Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunology, Immunotherapy, 55(8), 1011 - 1016. doi:10.1007/s00262-005-0095-5
    • Bellier B, Clerc B, Desjardins D, Klatzmann D, Dalba C, Drury R, Cosset F-L, Collins M (2006). DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine, 24(14), 2643 - 2655. doi:10.1016/j.vaccine.2005.11.034
    • Noser JA, Towers GJ, Sakuma R, Dumont JM, Collins MK, Ikeda Y (2006). Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. Journal of Virology, 80, 7769 - 7774.

    2005

    • Chan L, Nesbeth D, MacKey T, Galea-Lauri J, Gaken J, Martin F, Collins M, Mufti G, Farzaneh F, Darling D (2005). Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells. Journal of Virology, 79, 13190 - 13194.
    • Relander T, Johansson M, Olsson K, Ikeda Y, Takeuchi Y, Collins M, Richter J (2005). Gene transfer to repopulating human CD34(+) cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. MOL THER, 11(3), 452 - 459. doi:10.1016/j.ymthe.2004.10.014
    • Strang BL, Takeuchi Y, Relander T, Richter J, Bailey R, Sanders DA, Collins MK, Ikeda Y (2005). HIV-1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells. Journal of Virology, 79, 1765 - 1671.
    • Strang BL, Takeuchi Y, Relander T, Richter J, Bailey R, Sanders DA, Collins MK, Ikeda Y (2005). Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells.. J Virol, 79(3), 1765 - 1771. doi:10.1128/JVI.79.3.1765-1771.2005
    • Willoughby EA, Collins MK (2005). Dynamic interaction between the dual specificity phosphatase MKP7 and the JNK3 scaffold protein beta-arrestin 2. Journal of Biological Chemistry, 280, 25651 - 25658.
    • Relander T, Johansson M, Olsson K, Ikeda Y, Takeuchi Y, Collins MK, Richter J (2005). Gene transfer to repopulating CD34+ cells using amphotropic, GALV or RD114 pseudotyped HIV-1 based vectors from stable producer cells. Molecular Therapy, 11, 425 - 429.

    2004

    • Strang BL, Ikeda Y, Cosset FL, Collins MK, Takeuchi Y (2004). Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells. Gene Therapy, 11(7), 591 - 598.
    • Collins MK, Cerundolo V (2004). Gene therapy meets vaccine development. Trends in Biotechnology, 22, 623 - 626.
    • Rowe H, Lopes L, Ikeda Y, Collins M (2004). Lentivectors as vaccines.
    • Chowdhury S, Chester KA, Bridgewater J, Collins MK (2004). Efficient retroviral vector targeting of carcinoembryonic antigen-positive tumors. Molecular Therapy, 9(1), 85 - 92.
    • Palmowksi MJ, Lopes L, Ikeda Y, Salio M, Cerundolo V, Collins MK (2004). Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. The Journal of Immunology, 172(3), 1582 - 1587.
    • Bartosch B, Stefanidis D, Myers R, Weiss RA, Patience C, Takeuchi Y (2004). Evidence and consequence of porcine endogenous retrovirus recombination. Journal of Virology, 78(24), 13880 - 13890. doi:10.1128/JVI.78.24.13880-13890.2004
    • Richter J, Johansson M, Relander T, Olsson K, Ikeda Y, Takeuchi Y, Collins M (2004). Gene transfer to repopulating human CD34+cells using amphotropic, GALV or RD114 pseudotyped HIV-1 based vectors from stable producer cells..

    2003

    • Relander T, Johansson M, Olsson K, Ikeda Y, Takeuchi Y, Collins M, Richter J (2003). Gene transfer to repopulating human CD34+cells using amphotropic or RD114 pseudotyped HIV-1 based vectors from permanent producer cell lines (STAR).
    • Ikeda Y, Takeuchi Y, Martin F, Cosset FL, Mitrophanous K, Collins MK (2003). Continuous high-titre HIV-1 vector production. Nature Biotechnology, 21(5), 569 - 572. doi:10.1038/nbt815
    • Willoughby EA, Perkins GR, Collins MK, Whitmarsh A (2003). The JIP-1 scaffold protein targets MKP-7 to dephosphorylate JNK. Journal of Biological Chemistry, 278, 10731 - 10736.
    • Collins M (2003). Engineering retroviruses for gene delivery.
    • Martin F, Chowdhury S, Neil SJ, Chester KA, Cosset FL, Collins MK (2003). Targeted retroviral infection of tumor cells by receptor cooperation. Journal of Virology, 77(4), 2753 - 2756.
    • Zhao Y, Azam S, Collins MKL, Thorpe R (2003). Safety evaluation of lentiviral vectors.
    • Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C, Collins M (2003). KSHV vFLIP binds to IKK-gamma to activate IKK. Journal of Cell Science, 116, 3721 - 3728.
    • Andrawiss M, Takeuchi Y, Hewlett L, Collins MK (2003). Murine leukemia virus particle assembly quantitated by fluorescence microscopy: role of gag-gag interactions and membrane association. Journal of Virology, 77, 11651 - 11660. doi:10.1128/JVI.77.21.11651-11660.2003
    • Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C, Collins MK (2003). KSHV vFLIP binds to IKKg to activate IKK. Journal of Cell Science, 116, 3721 - 3728.
    • Willoughby EA, Perkins GR, Collins MK, Whitmarsh AJ (2003). The JNK-interacting protein-1 scaffold protein targets MAPK phosphatase-7 to dephosphorylate JNK.. J Biol Chem, 278(12), 10731 - 10736. doi:10.1074/jbc.M207324200

    2002

    • Towers G, Collins MK, Takeuchi Y (2002). Abrogation of Ref1 restriction in human cells. Journal of Virology, 76(5), 2548 - 2550. doi:10.1128/jvi.76.5.2548-2550.2002
    • Martin F, Chowdhury S, Neil S, Phillipps N, Collins MK (2002). Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. Molecular Therapy, 5(3), 269 - 274.
    • Ikeda Y, Collins MK, Radcliffe PA, Mitrophanous KA, Takeuchi Y (2002). Gene transduction efficiency in cells of different species by HIV and EIAV vectors. Gene Therapy, 9(14), 932 - 938.

    2001

    • Low W, Harries M, Ye HT, Du MQ, Boshoff C, Collins M (2001). Internal ribosome entry site regulates translation of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein. Journal of Virology, 75(6), 2938 - 2945.
    • Palacios C, Collins MK, Perkins GR (2001). The JNK phosphotase M3/6 is inhibited by protein-damaging stress. Current Biology, 11(18), 1439 - 1443.
    • Low W, Olmos-Centenera G, Madsen C, Leverrier Y, Collins MK (2001). Role of Bax in apoptosis of IL-3-dependent cells. ONCOGENE, 20(33), 4476 - 4483.
    • Neil S, Martin F, Ikeda Y, Collins M (2001). Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. Journal of Virology, 75(12), 5448 - 5456. doi:10.1128/JVI.75.12.5448-5456.2001
    • Low W, Harries M, Ye H, Du MQ, Boshoff C, Collins M (2001). Internal ribosome entry site regulates translation of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein.. J Virol, 75(6), 2938 - 2945. doi:10.1128/JVI.75.6.2938-2945.2001
    • Wood MK, Abayasiriwardana KS, Low W, Collins MK, Laurent GJ, Mcanulty RJ, Mutsaers SE (2001). Tumour enhancing effects of TGF beta in Malignant Mesothelioma are not inhibited by blocking the Smad pathway.
    • Collins M (2001). Modifying antigen presenting cells. CANCER GENE THERAPY, 8(11), 910 - 911.

    2000

    • Harries M, Phillipps N, Anderson R, Prentice G, Collins M (2000). Comparison of bicistronic retroviral vectors containing internal ribosome entry sites (IRES) using expression of human interleukin-12 (IL-12) as a readout.. J Gene Med, 2(4), 243 - 249. doi:10.1002/1521-2254(200007/08)2:4<243::AID-JGM115>3.0.CO;2-Q
    • Palacios C, Gutierrez DA, Silva A, Collins MK (2000). The role of p53 in death of IL-3-dependent cells in response to cytotoxic drugs. ONCOGENE, 19(31), 3556 - 3559.
    • Harries M, Phillipps N, Anderson R, Prentice G, Collins M (2000). Comparison of bicistronic retroviral vectors containing internal ribosome entry sites (IRES) using expression of human interleukin-12 (IL-12) as a readout. The Journal of Gene Medicine, 2(4), 243 - 249.
    • Palmer KJ, Harries M, Gore ME, Collins MK (2000). Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clinical and Experimental Immunology, 119(3), 412 - 418.
    • Zhao Y, Low W, Collins MK (2000). Improved safety and titre of murine leukaemia virus (MLV)-based retroviral vectors. Gene Therapy, 7(4), 300 - 305.

    1999

    • Palmer K, Moore J, Everard M, Harris JD, Rodgers S, Rees RC, Murray AK, Mascari R, Kirkwood J, Riches PG, Fisher C, Thomas JM, Johnston SRD, Collins MKL, Gore ME (1999). Gene therapy with autologous, interleukin-2-secreting tumour cells in patients with malignant melanoma increases circulating anti-tumour cytotoxic T lymphocytes. Human Gene Therapy, 10, 1261 - 1268.
    • Low W, Smith A, Ashworth A, Collins MKL (1999). JNK activation is not required for Fas-mediated apoptosis. Oncogene, 18, 3737 - 3741.
    • Martin F, Neil S, Kupsch J, Maurice M, Cossett F, Collins MKL (1999). Retrovirus targeting by tropism restriction to melanoma cells. Journal of Virology, 73, 6923 - 6929.
    • Maurice M, Mazur S, Bullough FJ, Salvetti A, Collins MKL, Russell SJ, Cosset FL (1999). Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelopes glycoproteins. BLOOD, 94(2), 401 - 410.
    • Low W, Smith A, Ashworth A, Collins M (1999). JNK activation is not required for Fas-mediated apoptosis. ONCOGENE, 18(25), 3737 - 3741.
    • Maurice M, Mazur S, Bullough FJ, Salvetti A, Collins MKL, Russell SJ, Cossett F (1999). Efficient gene delivery to quiescent IL2-dependent cells by MLV-derived vectors harboring IL2 chimeric envelope glycoproteins. Blood, 94, 410 - 410.

    1998

    • Porter C, Lukacs K, Box G, Takeuchi Y, Collins MKL (1998). Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo. Journal of Virology, 72, 4832 - 4840.
    • Martin F, Kupsch G, Cosset FL, Russell S, Takeuchi Y, Collins MKL (1998). Retroviral vector targetingto melanoma cells by single-chain antibody incorporation in envelope. Human Gene Therapy, 9, 737 - 746.

    1997

    • Silva A, Wyllie A, Collins M (1997). p53 is not required for regulation of apoptosis or radioprotection by IL-3. Blood, 8, 2717 - 2722.
    • Flemming C, Patel P, Box G, Eccles S, Collins M (1997). Sarcoma cells engineered to secrete IFN-gamma or IL-2 acquire sensitisation to immune cell killing via different mechanisms. Cytokine, 9, 328 - 332.
    • Furlong I, Ascaso R, Lopez-Rivas A, Collins M (1997). Intracellular acidification induces apoptosis by stimulating ICE-like protease activity. Journal of Cell Science, 110, 653 - 661.
    • Shi Y, Wang R, Sharma A, Gao C, Collins M, Penn L, Mills G (1997). Dissociation of cytokine signals for proliferation and apoptosis. J IMMUNOL, 159, 5318 - 5328.
    • Oliver F, Collins M, Lopez-Rivas A (1997). Overexpression of a heterologous thymidine kinase delays apoptosis induced by factor deprivation and inhibitors of deoxynucleotide metabolism. Journal of Biological Chemistry, 272, 10624 - 10630.
    • Leverrier Y, Thomas J, Perkins G, Manganey M, Collins M, Marvel J (1997). In bone marrow derived Baf-3 cells, inhibition of apoptosis by IL-3 is mediated by two independent pathways. Oncogene, 14, 425 - 430.
    • SMITH A, Ramos M, Ashworth A, Collins M (1997). A role for JNK/SAPK in proliferation but not apoptosis of IL-3 dependent cells. Current Biology, 7, 893 - 896.

    1996

    • Takeuchi Y, Porter CD, Strahan KM, Preece AF, Gustafsson K, Cosset FL, Weiss RA, Collins MK (1996). Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature, 379(6560), 85 - 88.
    • Porter CD, Collins MKJ, Tailor CS, Parkar MH, Cossett F-L, Weiss RA, Takeuchi Y (1996). Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Human Gene Therapy, 7, 913 - 919.
    • Gaken JA, Tavassoli M, Gan SU, Vallian S, Giddings I, Darling DC, Galea-Lauri J, Thomas MG, Abedi H, Schreiber V, Menissier-de Murcia J, Collins MK, Shall S, Farzaneh F (1996). Efficient retroviral infection of mammalian cells is blocked by inhibition of poly(ADP-ribose) polymerase activity. Journal of Virology, 70(6), 3992-4000 - .
    • Porter CD, Parkar MH, Collins MLK, Levinsky RJ, Kinnon C (1996). Efficient retroviral transduction of human bone marrow progenitor and long-term culture initiating cells: partial reconstitution of cells from patients with X-linked chronic granulomatous disease by gp91-phox expression. Blood, 87(9), 3722 - 3730.

    1995

    • Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, Russell SJ (1995). Retroviral retargeting by envelopes expressing an N-terminal binding domain. Journal of Virology, 69(10), 6314 - 6322.
    • TOWERS G, HARRIS J, LANG G, COLLINS MKL, LATCHMAN DS (1995). RETINOIC ACID INHIBITS BOTH THE BASAL ACTIVITY AND PHORBOL ESTER-MEDIATED ACTIVATION OF THE HIV LONG TERMINAL REPEAT PROMOTER. AIDS, 9(2), 129 - 136.
    • Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK (1995). High-titer packaging cells producing recombinant retroviruses resistant to human serum. Journal of Virology, 69(12), 7430 - 7436.

    1994

    • Porter CD, Parkar MH, Verhoeven AJ, Levinsky RJ, Collins MKL, Kinnon C (1994). p22-phox-deficient chronic granulomatous disease: reconstitution by retrovirus-mediated expression and identification of a biosynthetic intermediate of gp91-phox. Blood, 84(8), 2767 - 2775.
    • Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MK (1994). Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. Journal of Virology, 68(12), 8001 - 8007.

    1993

    • Porter CD, Parkar MH, Levinsky RJ, Collins MKL, Kinnon C (1993). X-linked chronic granulomatous disease: correction of NADPH oxidase defect by retrovirus-mediated expression of gp91-phox. Blood, 82(7), 2196 - 2202.
    • Howard MK, Burke LC, Mailhos C, Pizzey A, Gilbert CS, Lawson WD, Collins MK, Thomas NS, Latchman DS (1993). Cell cycle arrest of proliferating neuronal cells by serum deprivation can result in either apoptosis or differentiation.. , , - .
    • Tailor CS, Takeuchi Y, O'Hara B, Johann SV, Weiss RA, Collins MK (1993). Mutation of amino acids within the gibbon ape leukemia virus (GALV) receptor differentially affects feline leukemia virus subgroup B, simian sarcoma-associated virus, and GALV infections. Journal of Virology, 67(11), 6737 - 6741.

    1992

    • Takeuchi Y, Vile RG, Simpson G, O'Hara B, Collins MK, Weiss RA (1992). Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus. Journal of Virology, 66(2), 1219 - 1222.
    • DUBOIS D, LEDERMANN JA, LINK EM, STAUSS H, COLLINS M (1992). MALIGNANT-MELANOMA. LANCET, 340(8825), 948 - 951.

    1990

    • Orchard K, Perkins N, Chapman C, Harris J, Emery V, Goodwin G, Latchman D, Collins M (1990). A T-cell protein which recognizes a palindromic DNA sequence in the negative regulatory element of the HIV-1 long terminal repeat with homology to steroid/thyroid hormone receptor binding sites. Biochemical Society Transactions, 18(4), 555 - 556.
    • Orchard K, Perkins N, Chapman C, Harris J, Emery V, Goodwin G, Latchman D, Collins M (1990). A novel T-cell protein which recognizes a palindromic sequence in the negative regulatory element of the human immunodeficiency virus long terminal repeat. Journal of Virology, 64(7), 3234 - 3239.

    1984

    • COLLINS MK, OWEN MJ (1984). STUDIES ON THE HUMAN T-CELL RECEPTOR FOR ANTIGEN. IMMUNOBIOLOGY, 167(1-3), 242 - 242.